Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
ABT-199 (Venetoclax)
BCL-2 is overexpressed in several hematologic malignancies, acting as a key regulator of the intrinsic apoptotic pathway by neutralizing pro-apoptotic molecules and inhibiting apoptosis. ABT-199 is an orally bioavailable, second-generation BH3-mimetic that specifically and potently inhibits BCL-2 (Ki<0.10 nM), highly selective over BCL-xL (Ki=48 nM, a 500-fold selectivity). It is the first small molecule targeting BCL-xL with such selectivity and potency, and currently in clinical trials for cancer treatment.
Catalog NO: CT-A199
Synonym: Venectoclax, GDC-0199
CAS NO: 1257044-40-8
Mol. Formula: C45H50ClN7O7S
MW: 868.4 (or, refer to Certificate of Analysis, batch-specific)
** 99.9% pure, in vivo Quality Material. A multi cycle recrystallized yellow powder. Anhydrous, validated by a spot-on Quantitative Elemental Analysis. Bulk stock!! Prompt.